This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Aortic valve Article Stenosis 
Cardiology Update
FEBRUARY 11, 2024
The NOTION trial, a pioneering study, sought to compare the long-term clinical and bioprosthesis outcomes of Transcatheter Aortic Valve Implantation (TAVI) versus Surgical Aortic Valve Replacement (SAVR) in patients with severe aortic valve stenosis (AS) at lower surgical risk.
124 
Heart BMJ
FEBRUARY 26, 2025
A significant proportion of patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) have concomitant coronary artery disease (CAD). The best way to treat these patients is contentious.
American College of Cardiology
MAY 24, 2024
What is the relationship between aortic valve calcification (AVC) and aortic stenosis (AS) severity in patients with suspected low-flow low-gradient AS?
72 
American College of Cardiology
SEPTEMBER 18, 2024
The goal of the AVATAR trial was to evaluate aortic valve replacement (AVR) compared with conservative therapy among patients with asymptomatic severe aortic stenosis.
64 
American College of Cardiology
APRIL 8, 2024
The goal of the DEDICATE-DZHK6 trial was to evaluate transcatheter aortic valve implantation (TAVI) compared with surgical aortic valve replacement (SAVR) among patients with severe aortic stenosis and low to intermediate surgical risk.
60 
American College of Cardiology
MAY 29, 2024
In this week’s View, Dr. Eagle looks at the diagnostic value of aortic valve calcification levels in the assessment of low-gradient aortic stenosis.
60 
American College of Cardiology
FEBRUARY 26, 2025
In this weeks View, Dr. Eagle looks at the potential exposure-dependent protective effect of SGLT2 inhibitors on aortic valve stenosis progression.
63 
Cardiology Update
FEBRUARY 26, 2024
Transcatheter aortic valve replacement (TAVR) is the standard treatment for severe aortic stenosis, but post-TAVR leaflet thrombus, identified by hypoattenuated leaflet thickening (HALT), poses potential risks like cerebral thromboembolic events. had thrombus at any aortic valve complex. Specifically, 14.2%
122 
Frontiers in Cardiovascular Medicine
FEBRUARY 11, 2025
Articles were analyzed with bibliometric tools such as CiteSpace and VOSviewer to identify key research trends, core authors, institutions, and research hotspots in AI applications for AVS.ResultsA total of 118 articles were analyzed, showing a significant increase in publications from 2014 onwards.
52 
American College of Cardiology
FEBRUARY 12, 2024
The goal of the NOTION trial was to compare outcomes after transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in unselected patients with severe degenerative aortic stenosis.
56 
American College of Cardiology
APRIL 4, 2024
The goal of the VIVA trial was to evaluate transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement (SAVR) among patients with severe aortic stenosis and a small aortic annulus.
49 
Frontiers in Cardiovascular Medicine
DECEMBER 13, 2023
Transcatheter aortic valve replacement (TAVR) is a relatively new treatment method for aortic stenosis (AS) and has been demonstrated to be suitable for patients with varying risk levels.
64 
American College of Cardiology
JULY 23, 2024
What is the association between plasma lipoprotein(a) [Lp(a)] concentrations and hemodynamic progression in patients with aortic stenosis?
56 American College of Cardiology
MARCH 26, 2024
Blaha, MD, MPH discuss Prevalence of Aortic Valve Calcium and the Long-Term Risk of Incident Severe Aortic Stenosis. In this interview, Richard A. Chazal MD, MACC and Michael J.
63 
American College of Cardiology
OCTOBER 28, 2024
The goal of the EARLY TAVR trial was to evaluate transcatheter aortic valve replacement (TAVR) compared with clinical surveillance among patients with asymptomatic severe aortic stenosis (stage C aortic stenosis).
63 
Frontiers in Cardiovascular Medicine
FEBRUARY 23, 2024
This concept should be applied when managing older patients with severe aortic stenosis. Although left ventricular wall hypertrophy is expected in patients with aortic stenosis, it should not be assumed that this is caused only by aortic stenosis.
69 
American College of Cardiology
DECEMBER 17, 2024
The following are key points to remember from a review on aortic stenosis (AS), heart failure (HF), and aortic valve replacement (AVR).
40 American College of Cardiology
APRIL 22, 2024
What is the 5-year incidence of valve reintervention after self-expanding CoreValve/Evolut transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR)?
69 
American College of Cardiology
FEBRUARY 18, 2025
The EARLY TAVR trial results demonstrate that early transcatheter aortic valve implantation in patients with asymptomatic severe aortic stenosis is superior to clinical surveillance in significantly reducing the composite primary outcome of death, stroke, or unplanned hospitalization for cardiovascular causes.
61 
American College of Cardiology
MARCH 6, 2024
What are the hemodynamic and clinical outcomes after transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) among patients with severe aortic stenosis (AS) and a small aortic annulus?
60 
American College of Cardiology
OCTOBER 28, 2024
The goal of the TAVR UNLOAD trial was to evaluate transcatheter aortic valve replacement (TAVR) compared with clinical surveillance among patients with chronic systolic heart failure and moderate aortic stenosis (stage B aortic stenosis).
49 American College of Cardiology
SEPTEMBER 24, 2024
What are the clinical features and prognosis of patients with high-gradient (HG) aortic stenosis (AS) with a calculated aortic valve area (AVA) of >1.0
49 
American College of Cardiology
MARCH 11, 2024
In these panel discussions, host Andrea Price, MS, AACC brings together Marian Hawkey, RN and Misty Theriot, BSN to explore best practices related to structural heart disease.
58 
European Journal of Heart Failure
JANUARY 31, 2024
ABSTRACT Patients with severe aortic stenosis (AS) may develop heart failure (HF), the presence of which has traditionally been deemed as a final stage in AS progression with poor outcomes. The use of transcatheter aortic valve replacement (TAVR) has become the preferred therapy for most patients with AS and concomitant HF.
40 
American College of Cardiology
DECEMBER 20, 2024
The goal of the SOLVE-TAVI trial was to compare the safety and efficacy of the Edwards Sapien S3 valve vs. Medtronics CoreValve among patients undergoing transcatheter aortic valve replacement (TAVR) for severe aortic stenosis.
45 American College of Cardiology
OCTOBER 28, 2024
The goal of the EVOLVED trial was to assess the safety and efficacy of early aortic valve replacement compared with conservative management among patients with asymptomatic severe aortic stenosis, normal ejection fraction (EF), and presence of myocardial fibrosis on cardiac magnetic resonance imaging (CMR).
49 
American College of Cardiology
NOVEMBER 13, 2024
What are clinical outcomes among patients with severe aortic stenosis (AS) and coronary artery disease (CAD) undergoing surgical aortic valve replacement (SAVR) plus revascularization versus transcatheter aortic valve replacement (TAVR) plus percutaneous coronary intervention (PCI)?
60 
American College of Cardiology
DECEMBER 19, 2024
The goal of the TCW trial was to test the noninferiority and, if positive, superiority, of percutaneous coronary intervention (PCI) with transcatheter aortic valve implantation (TAVI) compared with surgical aortic valve replacement (SAVR) and coronary artery bypass grafting (CABG) in severe aortic stenosis (AS) with comorbid coronary artery disease (..)
Frontiers in Cardiovascular Medicine
JANUARY 23, 2024
Aims The majority of patients with severe aortic stenosis (AS) planned for transcatheter aortic valve implantation (TAVI) are elective outpatients. In the present article, we report the study protocol of the ResKriVer-TAVI trial. Methods ResKriVer-TAVI will enroll AS patients planned for elective TAVI.
53 
Circulation
NOVEMBER 11, 2024
Heterogeneity was assessed using I2 statistics. All statistical analyses were conducted using Review Manager (Rev Man, Version 5.4; The Cochrane Collaboration, Copenhagen, Denmark).Results:After to 1.17, p=0.30, I2 3%).
40 American College of Cardiology
FEBRUARY 26, 2025
In a cohort of patients with severe aortic stenosis (AS) who underwent aortic valve replacement (AVR), the degree of myocardial fibrosis provides significant prognostic information in women and men.
61 The British Journal of Cardiology
FEBRUARY 20, 2024
Patients with bicuspid aortic valves (BAV) are predisposed to the development of aortic stenosis. We performed a pairwise meta-analysis, comparing the efficacy of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in patients with BAV.
40 
American College of Cardiology
MARCH 5, 2025
In this weeks View, Dr. Eagle looks at the optimal threshold for identifying a myocardial infarction (MI) after PCI.
49 
American College of Cardiology
JULY 2, 2024
The goal of the LANDMARK trial was to evaluate transcatheter aortic valve replacement (TAVR) with the Myval prosthesis compared with a contemporary prosthesis among patients with symptomatic severe aortic stenosis.
53 American College of Cardiology
OCTOBER 28, 2024
Two separate late-breaking clinical trials – EARLY TAVR and EVOLVED – presented at TCT 2024 explore whether early aortic valve intervention improves outcomes in patients with asymptomatic aortic stenosis (AS).
53 
American College of Cardiology
OCTOBER 29, 2024
The goal of the PROTECTED TAVR trial was to evaluate the efficacy of intraprocedural cerebral embolic protection (CEP) in reducing strokes among patients undergoing transfemoral TAVR for aortic stenosis.
45 American College of Cardiology
APRIL 7, 2024
The goal of the SMART trial was to evaluate a self-expanding valve compared with a balloon-expandable valve among patients with aortic stenosis and a small aortic annulus undergoing treatment with transcatheter aortic valve replacement (TAVR).
53 
The British Journal of Cardiology
FEBRUARY 20, 2024
Case description An 80-year-old woman with severe symptomatic aortic stenosis was scheduled for transcatheter aortic valve implantation (TAVI), following Heart Team decision. Pre-procedural computed tomography (CT) angiogram revealed an area-derived annulus diameter of 23.7 mm, and calcium spur which extended from.
52 American College of Cardiology
NOVEMBER 25, 2024
What are the procedural and clinical outcomes of balloon-expandable valves (BEVs) and self-expanding valves (SEVs) in Sievers type 1 bicuspid aortic valve (BAV) stenosis?
American College of Cardiology
MARCH 29, 2024
This technique is now employed in approximately 85% of all isolated aortic valve replacements. In the past decade, the U.S. has seen a 25-fold increase in the use of TAVR, with more than 100,000 performed annually. Despite this growth, there are notable gaps in the evidence.
American College of Cardiology
OCTOBER 29, 2024
In women with symptomatic, severe aortic stenosis (AS), TAVR with the balloon-expandable valve was superior to surgical aortic valve replacement in terms of the composite rate of death, stroke and rehospitalization at one-year follow-up, according to a pooled analysis of patient-level data from RHEIA and PARTNER 3 trials presented at TCT 2024.
49 Journal of Cardiovascular Pharmacology
NOVEMBER 21, 2023
Abstract: Transcatheter aortic valve replacement (TAVR) is an interventional procedure performed in patients with severe aortic stenosis and often required perioperative antiplatelet therapy. Most previous studies have focused on antiplatelet therapy following TAVR.
40 Circulation: Cardiovascular Imaging
OCTOBER 25, 2023
Circulation: Cardiovascular Imaging, Volume 16, Issue 11 , Page e016039, November 1, 2023.
40 Circulation: Cardiovascular Imaging
OCTOBER 25, 2023
Circulation: Cardiovascular Imaging, Volume 16, Issue 11 , Page e016088, November 1, 2023.
40
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content